This region has wide measles vaccine coverage (first dose ≥95%, second dose ≥65%) without any reported measles outbreaks since 20 years.
To determine the utility of focal high-dose-rate brachytherapy for localized prostate cancer, we investigated the impact on target coverage and dose to organs at risk (OARs) with hemigland (HG) compared with whole-gland (WG) treatment.
Second, HT provides excellent target coverage and dose homogeneity while sparing the organs at risk.
Dosimetric parameters attained with RapidArc concerning target coverage and dose homogeneity were satisfactory also in non-strongly heterogeneous regions.
The main parameters to be evaluated will be clinical target volume (CTV) coverage and dose to organs at risk (OAR).
Varicella vaccination coverage (1st dose) in children 18-36 mofths of age increased in two steps (38%, 51%, 53%, 53%, 66%and6868%); second-dose coverage reached 59% in the 2011 survey.
The EPI measles coverage (first dose of MCV) was high according to administrative estimates and from the results of vaccine coverage surveys in selected districts.
Results of target coverage and doses to critical structures were compared.
The plans were compared from the point of view of their target coverage and doses to organs-at-risk.
